Magali Provansal
Overview
Explore the profile of Magali Provansal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Courbiere B, Miquel L, Bottin P, Provansal M, Saias-Magnan J, Metzler-Guillemain C
J Assist Reprod Genet
. 2024 Jul;
41(9):2515-2520.
PMID: 39003655
Purpose: Only a few case reports have described heterotopic ovarian tissue transplantation (OTT) with the only objective of restoring ovarian function. Methods: Case report and review of the literature for ...
2.
de Nonneville A, Kalbacher E, Cannone F, Guille A, Adelaide J, Finetti P, et al.
Mol Oncol
. 2024 Jun;
18(10):2586-2600.
PMID: 38923749
Endometrioid ovarian cancers (EOvC) are usually managed as serous tumors. In this study, we conducted a comprehensive molecular investigation to uncover the distinct biological characteristics of EOvC. This retrospective multicenter...
3.
Nigon E, Lefeuvre-Plesse C, Martinez A, Chauleur C, Lortholary A, Favier L, et al.
J Transl Med
. 2023 Jun;
21(1):408.
PMID: 37353806
Background: Uterine clear cell carcinomas (CCC) represent less than 5% of uterine cancers. Their biological characteristics and clinical management remain uncertain. A multicenter study to explore both clinical and molecular...
4.
Hanvic B, Lecuru F, Vanacker H, Pautier P, Narducci F, Cherifi F, et al.
Gynecol Oncol
. 2023 May;
174:190-199.
PMID: 37210929
Objective: Identifying prognostic factors and evaluating the impact of adjuvant chemotherapy in patients with sex cord stromal tumors (SCST) is crucial. In this study, we aimed to address these challenges....
5.
Gauduchon T, Kfoury M, Lorusso D, Floquet A, Ventriglia J, Salaun H, et al.
Gynecol Oncol
. 2023 Apr;
173:98-105.
PMID: 37105063
Background: PARP inhibitors (PARPi) have revolutionized the management of high-grade epithelial ovarian cancer (HGOC) treatment. However, a significant number of patients relapse or progress under PARPi, leading to the introduction...
6.
Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione S, et al.
JCO Precis Oncol
. 2023 Jan;
7:e2200258.
PMID: 36716415
Purpose: The PAOLA-1/ENGOT-ov25 trial of maintenance olaparib plus bevacizumab for newly diagnosed advanced high-grade ovarian cancer demonstrated a significant progression-free survival (PFS) benefit over placebo plus bevacizumab, particularly in patients...
7.
Caillol F, Ratone J, Marx M, Dahel Y, Hoibian S, Provansal M, et al.
Endoscopy
. 2022 Nov;
55(S 01):E199-E200.
PMID: 36368666
No abstract available.
8.
Bini M, Quesada S, Meeus P, Rodrigues M, Leblanc E, Floquet A, et al.
Cancers (Basel)
. 2022 Aug;
14(16).
PMID: 36011033
Background: In spite of the frequency and clinical impact of alterations in high-grade epithelial ovarian cancer (HGEOC), real-world information based on robust data warehouse has been scarce to date. Methods:...
9.
Sabatier R, Garnier S, Guille A, Carbuccia N, Pakradouni J, Adelaide J, et al.
Front Oncol
. 2022 Aug;
12:946257.
PMID: 35965534
Introduction: The poor prognosis of ovarian carcinoma (OvC) is due to the advanced stage at diagnosis, a high risk of relapse after first-line therapies, and the lack of efficient treatments...
10.
Rives N, Courbiere B, Almont T, Kassab D, Berger C, Grynberg M, et al.
Eur J Cancer
. 2022 Aug;
173:146-166.
PMID: 35932626
Aim: To provide practice guidelines about fertility preservation (FP) in oncology. Methods: We selected 400 articles after a PubMed review of the literature (1987-2019). Recommendations: Any child, adolescent and adult...